• Home 1
  • Privacy Policy
LSD News
  • Home
  • Business
  • Crypto News
  • Finance
  • Health
  • Politics
  • Sports
  • Stock
  • Tech
  • Travel
No Result
View All Result
  • Home
  • Business
  • Crypto News
  • Finance
  • Health
  • Politics
  • Sports
  • Stock
  • Tech
  • Travel
No Result
View All Result
LSD News
No Result
View All Result
Home Health

FDA approves zuranolone, first pill for postpartum depression

by
August 5, 2023
in Health
0
FDA approves zuranolone, first pill for postpartum depression
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


The Food and Drug Administration announced Friday it has approved the first oral treatment for postpartum depression. The drug, called zuranolone, is a once-a-day pill that will be branded as Zurzuvae by drugmakers Sage Therapeutics and Biogen. 

Zuranolone is approved for use in adults for the treatment of postpartum depression, an episode of major depression that can begin after childbirth or the later stages of pregnancy, which affects an estimated 15% of women in the weeks or months after having a baby.

“Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings,” Dr. Tiffany Farchione, director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, said in a statement.

Before this, the only approved option for treating postpartum depression was also from Sage Therapeutics: brexanolone, which is marketed as Zulresso and must be administered as an IV infusion. It was approved by the FDA in 2019 as the first treatment specifically for postpartum depression.

Similar to that drug, Sage and Biogen say they think zuranolone acts as a steroid that binds to GABA receptors within the brain, working to effectively reset neurotransmitters thrown off in patients struggling with depression.

“In people with depression, it may help to rapidly rebalance dysregulated neuronal networks to help restore brain function. Zuranolone targets brain networks responsible for functions such as mood, arousal, behavior, and cognition,” the companies said in a release last year.

Zuranolone’s label will carry a boxed warning that patients should not drive or operate machinery for 12 hours after taking the drug.  The FDA says the most common side effects include drowsiness, dizziness, diarrhea, fatigue, the common cold and urinary tract infection. There is a risk of suicidal thoughts. The drug may cause fetal harm, so women taking it should use contraception, the FDA says. 

The drug will need to clear a 90-day Drug Enforcement Agency scheduling process, the companies said, before it can enter the market.

Not approved for major depression

The companies had touted the once-daily pill, intended to be taken over only two weeks, as part of a potential new “paradigm” for how major depression might soon be treated. They sought FDA approval for it to treat both postpartum depression and major depressive disorder. 

However, with Friday’s decision, the FDA only formally approved the drug for postpartum depression.

While doctors generally are able to prescribe treatments for unapproved “off-label” reasons, the lack of an approval restricts drugmakers from marketing the pills for those uses.

It was not immediately clear what concerns prevented the FDA from approving the drug for major depressive disorder. 

Spokespeople for Sage Therapeutics and the FDA did not immediately respond to a request for comment. 

The drugmakers had cited several promising recent results for the drug, including successes in treating both major depressive disorder and postpartum depression.

In a recent clinical trial, researchers said a14-day course of zuranolone pills appeared to help stave off further depressive episodes in many patients for months before another round of the medication might need to be taken. 

That is different from many common antidepressants, like selective serotonin reuptake inhibitors or SSRIs, which are typically prescribed to be taken over a longer term.

But those findings followed earlier setbacks for the company back in 2019, after the drugmakers disclosed a key Phase 3 study of the treatment fell short of its goal to outperform a placebo in “a statistically significant reduction” for treating depression. 

At the time, Sage Therapeutics said their data found some patients in the study had no measurable drug concentration in their body, suggesting they had missed their doses and muddied the results.  

“We see a consistent improvement in depressive symptoms associated with zuranolone, over that of placebo. Specifically, five out of six of these placebo controlled clinical studies resulted in a statistically significant improvement in depressive symptoms,” Dr. Maha Radhakrishnan, Biogen’s chief medical officer, had said in a December call outlining their plans to market the drug for both approaches. 

Alexander Tin

CBS News reporter covering public health and the pandemic.

Tags: ApprovesdepressionFDApillPostpartumzuranolone
Previous Post

Trump Indictment Presents New Obstacle in Spending Fight as Shutdown Looms

Next Post

Global X Refiles Spot-Bitcoin ETF Application, Naming Coinbase as ‘Surveillance-Sharing’ Partner

Next Post
Global X Refiles Spot-Bitcoin ETF Application, Naming Coinbase as ‘Surveillance-Sharing’ Partner

Global X Refiles Spot-Bitcoin ETF Application, Naming Coinbase as ‘Surveillance-Sharing’ Partner

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected test

  • 139 Followers
  • 205k Subscribers
  • 23.9k Followers
  • 99 Subscribers
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Hawaii officials work to address mental health challenges facing wildfire survivors

Hawaii officials work to address mental health challenges facing wildfire survivors

August 17, 2023
Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs

Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs

August 10, 2023
Contact lens maker faces lawsuit after woman said the product resulted in her losing an eye

Contact lens maker faces lawsuit after woman said the product resulted in her losing an eye

July 16, 2023
Working-age Americans are struggling to pay for health care, even those with insurance, report finds

Working-age Americans are struggling to pay for health care, even those with insurance, report finds

October 28, 2023
Tech layoffs in Southeast Asia mount as unprofitable startups seek to extend their runways

Tech layoffs in Southeast Asia mount as unprofitable startups seek to extend their runways

5
Contact lens maker faces lawsuit after woman said the product resulted in her losing an eye

Contact lens maker faces lawsuit after woman said the product resulted in her losing an eye

5
Why Cristiano Ronaldo’s move to Saudi Arabia means so much for the Gulf monarchy’s sporting ambitions | CNN

Why Cristiano Ronaldo’s move to Saudi Arabia means so much for the Gulf monarchy’s sporting ambitions | CNN

3
Georgia realtor receives invitation to play the Masters by mistake | CNN

Georgia realtor receives invitation to play the Masters by mistake | CNN

1
Abdul Wazeeth takes oath as SLMC National List MP

Abdul Wazeeth takes oath as SLMC National List MP

July 8, 2025
10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

July 8, 2025
Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, died while leading campers to safety during the devastating floods

Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, died while leading campers to safety during the devastating floods

July 8, 2025
Samsung expects second-quarter profits to more than halve as it struggles to capture AI demand

Samsung expects second-quarter profits to more than halve as it struggles to capture AI demand

July 8, 2025

Recent News

Abdul Wazeeth takes oath as SLMC National List MP

Abdul Wazeeth takes oath as SLMC National List MP

July 8, 2025
10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

July 8, 2025
Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, died while leading campers to safety during the devastating floods

Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, died while leading campers to safety during the devastating floods

July 8, 2025
Samsung expects second-quarter profits to more than halve as it struggles to capture AI demand

Samsung expects second-quarter profits to more than halve as it struggles to capture AI demand

July 8, 2025

We bring the latest news from all over the world and get all time updated you

Follow Us

Browse by Category

  • Business
  • Crypto News
  • Finance
  • Health
  • Politics
  • Sports
  • Stock
  • Tech
  • Travel
  • Uncategorized

Recent News

Abdul Wazeeth takes oath as SLMC National List MP

Abdul Wazeeth takes oath as SLMC National List MP

July 8, 2025
10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

10 Nifty large-cap stocks with up to 38 buy calls; analysts see up to 20% upside – Top Picks

July 8, 2025
No Result
View All Result
  • Home 1
  • Privacy Policy

© 2024 LSD News title="Jegtheme">Jegtheme.